Reporting Cases of Telogen Effluvium as a sequelae of COVID‐19 Infection
Abstract
Objective: to report cases of Telogen effluvium (T.E) as a sequele of COVID 19
Material and methods: Ten patients were reported between May and august 2021with median age group of 21years. There were five males and five females in the study. All the cases were diagnosed with positive RTPCR when they had COVID and recovered fully without need for hospitalization. T.E occurred in our group after median of two months (range 1-2months) following COVID 19 infection. Detailed medical history of all the patients was taken.
Results: all the ten cases showed early onset of T.E within three months of infection.
Keywords: Telogen Effluvium, Covid 19, RTPCR
Keywords:
Telogen Effluvium, Covid 19, RTPCRDOI
https://doi.org/10.22270/jddt.v12i1.5309References
Marraha F, Al Faker I, Gallouj S, “A review of the dermatological manifestations of coronavirus disease 2019 (COVID‐19)”Dermatol Res Pract 2020; 2020:9360476. [PMC free article] [PubMed] [Google Scholar] https://doi.org/10.1155/2020/9360476
Kligman AM., “Pathologic dynamics of human hair loss: I. Telogen effluvium” ArchDermatol.1961; 83:175-198. https://doi.org/10.1155/2020/9360476
Headington JT: Telogen effluvium: new concepts and review. Arch Dermatol.1993; 129:356- 363. https://doi.org/10.1001/archderm.1993.01680240096017
Asghar F, Shamim N, Farooque U, “Telogen Effluvium: A Review of the Literature” Cureus.2020; 12(5):8320. https://doi.org/10.7759/cureus.8320
Rossi A, Magri F, Sernicola A, Michelini S, Marta GC, Marco Di M, Camilla F, Maria C, Fortuna C, Grieco T, “Telogen Effluvium after SARS-CoV-2 Infection: A Series of Cases and Possible Pathogenetic Mechanisms” Skin Appendage Disord 2021; 7:377–381https://doi.org/10.1159/000517223
Rivetti N, Barruscotti S, “Management of telogen effluvium during the COVID-19 emergency:psychological implications” Dermatol Ther. 2020; 33(4):e13648 https://doi.org/10.1159/000517223
Santas M D, Martinez L H, Nieto D F, Cauhe J H,Valle A S, Guimaraens B D. “Acute telogen effluvium associated with SARSCoV-2 infection”. Aust J Gen Pract. 2022; 26(49):49
Published
Abstract Display: 297 
PDF Downloads: 258 PDF Downloads: 29 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.